RxDoctor Payments Data

Marissa Wedel, MD

Ophthalmology · Camp Hill, PANPI 1649434796

Payments from drug & device makers

$800in general payments, 2019–2025

Across 25 payments — averaging $32.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$202
  • AbbVie$157
  • Regeneron Healthcare Solutions, Inc.$139
  • Carl Zeiss Meditec USA, Inc.$103
  • Alimera Sciences, Inc.$94
  • Alcon$85
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$800100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$800 in reported general payments places this provider in the 35th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,351,290
Medicare patients
678
Services billed
36,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EyleaAflibercept38$98,971
Bromfenac Sodium28$3,308
Difluprednate34$3,199
Prednisolone Acetate69$2,343
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha150$1,626
Atropine Sulfate31$1,171
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat40$576
Brimonidine Tartrate29$562
Acetazolamide ErAcetazolamide16$278
Ketorolac Tromethamine15$193
Timolol Maleate12$144
Ofloxacin12$127
ErythromycinErythromycin Base11$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Regeneron Healthcare Solutions, Inc.Eylea$139$98,97138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Camp Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →